Related Experiment Video

Updated: Jun 24, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Chloroquine in glioblastoma--new horizons for an old drug

Anusheel Munshi1

  • 1Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India. anusheel8@hotmail.com

Cancer
|March 28, 2009
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 24, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Use of a novel tongue-sparing intraoral prosthesis for radiation therapy in a head and neck patient: A case report.

Indian journal of cancer·2026

Carbon footprint generated by a radiation oncology department at a tertiary care hospital in India - A single institution analysis.

Journal of cancer research and therapeutics·2026

Multidisciplinary Team Care for Early-Stage Lung Cancer in Low- and Middle-Income Countries and Emerging Economies: Current Position and Call for Action.

Thoracic cancer·2026

Consensus Building for Radiotherapy Quality Assurance: A Multicenter Methodological Narrative From India (Standardised Unified Radiotherapy Quality Assurance).

JCO global oncology·2026

Dosimetric evaluation and clinical feasibility of Halcyon-E O-ring linear accelerator for single fraction coplanar stereotactic radiosurgery.

Journal of medical imaging and radiation sciences·2026

Commissioning of Bilateral (Parallel Opposed) Extended Source-to-surface Distance Total Body Irradiation Technique and Its Long-term Stability.

Journal of medical physics·2026

Real-world outcomes in circulating tumor DNA-detected isocitrate dehydrogenase 1-mutant cholangiocarcinoma: First-line gemcitabine and cisplatin with versus without immunotherapy.

Cancer·2026

Cancer risks associated with BRCA1 and BRCA2: Overview and management.

Cancer·2026

Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.

Cancer·2026

Evolving role of proton therapy in contemporary oncology.

Cancer·2026

Evaluation of early C-reactive protein kinetics as an early response marker in biliary tract cancer treated with combined chemoimmunotherapy: A multicenter observational study.

Cancer·2026

Delays in breast cancer presentation, diagnosis, and treatment in young women.

Cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us